Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Raymond James Downgrades Voyager Therapeutics (VYGR) to Market Perform
December 23, 2020 9:20 AM ESTRaymond James analyst Reni Benjamin downgraded Voyager Therapeutics (NASDAQ: VYGR) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $8.00 yesterday.
... More